WOBURN, Mass. - A recent study has highlighted the effectiveness of NeuroMetrix, Inc.'s (NASDAQ:NURO) DPNCheck as a diagnostic tool for diabetic peripheral neuropathy (DPN), a common complication in diabetes patients. The research, led by Hayashi and colleagues, involved 167 individuals with Type 1 or Type 2 diabetes and used nerve conduction studies as the reference standard for diagnosing DPN.
The study introduced a predictive formula incorporating DPNCheck measurements, patient age, and the coefficient of variation of R-R intervals (CVR-R) from standard EKGs. The combination of DPNCheck with CVR-R, as well as the use of DPNCheck alone, showed high diagnostic performance, with an area under the receiver operating curve of 0.88.
Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix, stated that this study adds to the growing scientific evidence supporting DPNCheck's diagnostic accuracy, which has been validated in over 10 independent studies involving more than 1,500 diabetes patients. Gozani contrasted DPNCheck's accuracy with the traditional monofilament testing, which has been criticized for its low accuracy and reliability in a recent large multi-center study.
DPN is a significant complication for those with diabetes, leading to chronic nerve pain, foot ulcers, and increased risk of falls, especially in older adults. It is associated with a marked decline in quality of life and daily activities. DPNCheck is designed for use by clinicians to detect and monitor peripheral neuropathies at an early stage when interventions can be most effective.
NeuroMetrix is known for developing neurotechnology devices to meet the needs of patients with chronic pain and diabetes. Alongside DPNCheck, the company offers Quell, a wearable neuromodulation platform. Both products are part of NeuroMetrix's commitment to innovative medical solutions.
The information in this article is based on a press release statement from NeuroMetrix, Inc.
InvestingPro Insights
In the wake of the study showcasing the effectiveness of NeuroMetrix, Inc.'s DPNCheck, it's pertinent to look at the company's financial health and market performance to understand its potential trajectory. According to InvestingPro data, NeuroMetrix currently holds a market capitalization of 7.57 million USD, which reflects its size within the medical device industry. Despite facing challenges, as indicated by a negative revenue growth rate of -28.52% over the last twelve months as of Q4 2023, the company maintains a strong gross profit margin of 66.89%, suggesting it retains a significant portion of its revenue after accounting for the cost of goods sold.
InvestingPro Tips reveal a mixed picture for NeuroMetrix. On the positive side, the company holds more cash than debt on its balance sheet, which is a good indicator of financial stability. Additionally, analysts predict that NeuroMetrix will experience net income and sales growth in the current year, pointing towards a potential turnaround. However, it's important to note that the company has been quickly burning through cash and has not been profitable over the last twelve months, which investors should consider when evaluating the stock.
For those interested in a deeper dive into NeuroMetrix's financials and stock performance, InvestingPro offers an array of tips, including 11 additional insights that could help investors make more informed decisions. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and unlock the full potential of InvestingPro's analysis. With the next earnings date scheduled for April 26, 2024, and the InvestingPro Fair Value estimated at 5.51 USD, significantly above the previous close price of 3.92 USD, there may be opportunities that savvy investors can capitalize on.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.